Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $22 and keeps a Buy rating on the shares. Miplyffa’s launch continues to perform well, with FY25 results showing “a clear acceleration,” says the analyst, who expects steady growth to continue as Miplyffa further penetrates the U.S. market and retention remains high.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strong NPC Enrollment Momentum and Undervalued Rare-Disease Pipeline Support Buy Rating and $26 Target
- Zevra Therapeutics Appoints Justin Renz as New CFO
- Zevra Therapeutics reports Q4 EPS 20c, consensus 5c
- Zevra Therapeutics Inc options imply 4.6% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 09, 2026